The latest announcement is out from Meiragtx Holdings ( (MGTX) ).

MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s disease, showcasing significant improvements in both motor function and quality of life. The study demonstrated an 18-point average improvement in motor scores for the high dose group and noted meaningful enhancements in patient-reported outcomes, with no serious adverse events reported. This progress paves the way for a potential Phase 3 trial, aiming to position AAV-GAD as a groundbreaking treatment for Parkinson’s globally.

For a thorough assessment of MGTX stock, go to TipRanks’ Stock Analysis page.